Login to Your Account



Hutchinson expands its TCM commercial operation as its pipeline revs up

By Shannon Ellis
Staff Writer

Wednesday, June 4, 2014

SHANGHAI – Hutchinson China Meditech Ltd. (Chi-Med) has struck a new deal with its joint venture partner of 13 years, Shanghai Traditional Chinese Medicine Co. Ltd. (STCM), to exclusively sell six prescription drugs in China. Chi-Med's commercial operations help to fund its extensive R&D efforts with seven candidates in the clinic for oncology, immunology and inflammation.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription